Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Double-Blind Study of Mometasone Furoate Versus Placebo in the Prevention of Radiation Dermatitis in Breast Cancer Patients Receiving Radiation Therapy

NCT00438659 is registered in ClinicalTrials.gov with North Central Cancer Treatment Group as lead sponsor.

NCT NCT00438659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00438659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Double-Blind Study of Mometasone Furoate Versus Placebo in the Prevention of Radiation Dermatitis in Breast Cancer Patients Receiving Radiation Therapy
Lead sponsor
North Central Cancer Treatment Group
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2007
Completion date
June 30, 2014
Enrollment
176 (actual)
Sites
189

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, dermatologic complications, radiation toxicity, skin reactions secondary to radiation therapy